A Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis

  • End date
    Oct 11, 2023
  • participants needed
  • sponsor
    Horizon Therapeutics Ireland DAC
Updated on 11 September 2021
idiopathic pulmonary fibrosis
diffusion capacity of the lung for carbon monoxide


This is a randomized, double-blind, placebo-controlled, repeat-dose, multicenter trial to evaluate the efficacy, safety and tolerability of HZN-825 in subjects with IPF. Subjects will be screened within 8 weeks prior to the Baseline (Day 1) Visit. Approximately 360 subjects who meet the trial eligibility criteria will be randomly assigned in a 1:1:1 ratio on Day 1 to receive HZN-825 300 mg QD, HZN-825 300 mg BID or placebo for 52 weeks using the following 2 stratification factors:

  1. Prior use of approved IPF therapy (i.e., nintedanib or pirfenidone): yes or no
  2. FVC % predicted at Baseline: 70% or <70%

Condition Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, usual interstitial pneumonia
Treatment Placebo, HZN-825
Clinical Study IdentifierNCT05032066
SponsorHorizon Therapeutics Ireland DAC
Last Modified on11 September 2021


Yes No Not Sure

Inclusion Criteria

Written informed consent
Male or female between the ages of 18 and 80 years, inclusive, at Screening
Diagnosis of IPF, as defined by American Thoracic Society (ATS)/European Respiratory Society (ERS)/Japanese Respiratory Society (JRS)/Latin American Thoracic Society (ALAT) guidelines [Raghu et al., 2018]; the date of diagnosis of IPF should be 1 year to 7 years prior to Screening
Not currently being treated with specific IPF therapy for the reasons below
intolerant or not responsive to approved IPF therapies
ineligible to receive approved IPF therapies
declines approved IPF therapies
Lung HRCT historically performed within 6 months prior to the Screening Visit and according to the minimum requirements for IPF diagnosis by central review based on subject's HRCT. If an evaluable HRCT is not available within 6 months prior to Screening, an HRCT will be performed at Screening to determine eligibility, according to the same requirements as the historical HRCT
HRCT shows 10% to <50% parenchymal fibrosis (reticulation) and <25% honeycombing and the extent of fibrotic changes is greater than the extent of emphysema on the most recent HRCT scan (central reviewer determined)
Meets all of the following criteria during the Screening Period
FVC 45% and 80% predicted of normal
forced expiratory volume in 1 second (FEV1)/FVC 0.7
DLCO corrected for hemoglobin is 30% and 90% predicted of normal
Estimated minimum life expectancy of 30 months for non-IPF-related disease, in the opinion of the Investigator
Vaccinations are up to date given age, comorbidities (e.g., severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]), pneumococcal pneumonia, herpes zoster, tetanus) and local availability prior to trial drug dosing
Willing and able to comply with the prescribed treatment protocol and evaluations for the duration of the trial

Exclusion Criteria

Any of the following cardiovascular diseases
uncontrolled, severe hypertension (160/100 mmHg), within 6 months of Screening
myocardial infarction within 6 months of Screening
unstable cardiac angina within 6 months of Screening
Interstitial lung disease (ILD) associated with known primary diseases (e.g., sarcoidosis, amyloidosis and coronavirus disease 2019 [COVID-19]), connective tissue disorders (e.g., rheumatoid arthritis, systemic lupus erythematosus, Sjogren's, dermatomyositis, scleroderma), exposures (e.g., radiation, silica, asbestos and coal dust) or drugs (e.g., amiodarone)
Known active bacterial, viral, fungal, mycobacterial or other infection, including tuberculosis or atypical mycobacterial disease (fungal infections of nail beds are allowed). The subject must be 3 months beyond any acute infection with COVID-19 if there has been a prior infection
Clinically significant pulmonary hypertension requiring chronic medical therapy
Use of any of the following therapies within 4 weeks prior to Screening, during the Screening Period or planned during the trial: prednisone at steady dose >10 mg/day or equivalent or cyclosporine A. Prednisone 10 mg/day (or equivalent dosing of glucocorticoids) is allowed. Treatment with any other immunosuppressant during the Screening Period through the end of trial participation will require consultation with and approval by the trial Medical Monitor
Use of rifampin within 2 weeks prior to Day 1 or planned during the trial
Malignant condition in the past 5 years (except successfully treated basal/squamous cell carcinoma of the skin or cervical cancer in situ)
Women of childbearing potential (WOCBP) or male subjects not agreeing to use highly effective method(s) of birth control throughout the trial and for 1 month after last dose of trial drug. Male subjects must refrain from sperm donation and females from egg/ova donation for this same time period
Pregnant or lactating women and women who plan to become pregnant or breast feed during the trial and within 1 month after the last dose of trial drug
Current drug or alcohol abuse or history of either within the previous 2 years, in the opinion of the Investigator or as reported by the subject
Previous enrollment in this trial or participation in a prior HZN-825 or SAR100842 clinical trial
Known history of positive test for human immunodeficiency virus
Active hepatitis (hepatitis B: positive hepatitis B surface antigen and positive anti-hepatitis B core antibody [anti-HBcAb] and negative hepatitis B surface antibody [HBsAb] or positive for HBcAb with a positive test for HBsAb and with presence of hepatitis B virus DNA at Screening; hepatitis C: positive anti-hepatitis C virus [anti-HCV] and positive RNA HCV)
Current alcoholic liver disease, primary biliary cirrhosis or primary sclerosing cholangitis
Previous organ transplant (including allogeneic and autologous marrow transplant)
International normalized ratio >2, prolonged prothrombin time >1.5 the upper limit of normal (ULN) or partial thromboplastin time >1.5 ULN at Screening
Alanine aminotransferase or aspartate aminotransferase >2.0 ULN
Estimated glomerular filtration rate <30 mL/min/1.73 m2 at Screening
Total bilirubin >2 ULN. Subjects with documented diagnosis of Gilbert's syndrome may be enrolled if their total bilirubin is 3.0 mg/dL
Moderate (Child-Pugh B) to severe (Child-Pugh C) hepatic impairment according to the Child-Pugh scoring system
Any verified Grade 4 laboratory abnormality
Any acute laboratory abnormality at Screening that, in the opinion of the Investigator, would preclude the subject's participation in the trial
Exposure to an experimental drug (with the exception of HZN-825) or experimental vaccine within either 30 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is the longest, prior to Day 1
Any other condition that, in the opinion of the Investigator, would preclude enrollment in the trial
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note